Physician profile
Michael J Passarella
NPI 1396844197
$3,052.12
in general payments reported to CMS, 2019-2025
21 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.78 · 2022: $366 · 2023: $1,046 · 2024: $672 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.85 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.74 | 2022-2025 | |
| Janssen Biotech, INC. | $487.11 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $399.08 | 2022-2025 | Entyvio |
| Celgene Corporation | $239.83 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $207.09 | 2024-2025 | Voquezna |
| Pfizer INC. | $167.63 | 2023-2025 | |
| Ardelyx, INC. | $150.11 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.77 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Genzyme Corporation | $138.65 | 2022-2025 | |
| Lilly USA, LLC | $102.87 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $101.58 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $77.07 | 2023 | |
| Merck Sharp & Dohme LLC | $50.16 | 2019-2023 | Dificid |
| Exact Sciences Corporation | $38.83 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $32.97 | 2022-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $29.87 | 2023-2024 | Idacio |
| Ucb, INC. | $19.58 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.99 | 2023 | Ocaliva |
| Evoke Pharma, INC. | $16.81 | 2025 | |
| Gilead Sciences, INC. | $14.84 | 2023 | |
| Capsovision, INC. | $14.54 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Passarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.